Stoke Therapeutics is a biotechnology company focused on restoring protein expression using RNA medicine, specifically antisense oligonucleotides (ASOs). Their pipeline includes zorevunersen for Dravet syndrome (in Phase 3, partnered with Biogen) and STK-002 for autosomal dominant optic atrophy (ADOA) (in Phase 1). They also have early research in Syngap1 with Acadia Pharmaceuticals. Stoke's initial focus is on diseases of the central nervous system and the eye caused by haploinsufficiency, with broader potential demonstrated across other organs and tissues. The Medical Director, Neurology Clinical Development will provide strategic leadership for planning, execution, and interpretation of clinical studies focused on transformative therapies for life-threatening neurological diseases. This individual will be responsible for leading study design and execution and driving interpretation of data to support development decisions across one or more programs. The Medical Director will serve as a key leader within cross-functional teams and as an important representative of the program with investigators, consultants, and other key stakeholders. This role requires an experienced physician-drug developer who can operate with substantial independence, influence program direction, and ensure scientific and medical rigor from early development through late-stage studies. This role will report to the Vice President, Neurology Clinical Development.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Education Level
Ph.D. or professional degree
Number of Employees
11-50 employees